Gynecologic Oncology

In a recent study, the prediction values of cervical cancer prediction models increased significantly when human papillomavirus genotypes were included in the evaluation.

In a recent study, high sensitivity and specificity were found for differentiating between benign and malignant lesions when using the Assessment of Different Neoplasias in the Adnexa and Ovarian-Adnexal Reporting and Data System models.

Jeff Andrews, MD, FRCSC, Vice President of Medical Affairs for Integrated Diagnostic Solutions at BD, discusses the link between human papillomavirus (HPV) and cervical cancer, and how HPV self-sampling kits may increase rates of cervical cancer screening.

In a recent study, under-screened patients were more likely to receive cervical cancer screening after receiving at-home high-risk human papillomavirus sampling kits.

In a recent study, patients receiving interventions designed to increase adherence to screenings for breast, cervical, or colorectal cancers were more likely to be up to date on any or all screenings.

In a recent study, female patients born by cesarean delivery were more likely to experience early-onset colorectal cancer.

In a recent study, histologic subtype accounted for 54.1% of the excess relative risk for Black patients compared to White patients with uterine cancer.

In a recent study, women diagnosed with cancer during pregnancy and postpartum periods experienced greater rates of mortality than those diagnosed outside of pregnancy.

In a recent study, women taking higher cumulative dosages of hormone therapy had a reduced risk of developing lung cancer.

The FDA has granted a regular approval to dostarlimab-gxly (Jemperli; GSK) for adult patients with mismatch repair–deficient, recurrent or advanced endometrial cancer that has progressed on or after a prior platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation.

This month is a perfect opportunity for ob-gyns and other women’s health care providers to raise awareness about cervical cancer and HPV vaccination.

Teenaged girls at average risk don’t need Papanicolaou tests, but some special populations do.

Spot Her aims to educate people about the signs and risk factors of endometrial cancer, one of the most common yet under-recognized women’s cancers.

Drs Emily K. Hill, Sangini S. Sheth, and Mark H. Stoler, comment on the implementation considerations surrounding HPV and cervical cancer screening.

Uterine cancer is currently the only cancer type not covered by the World Trade Center (WTC) Health Program.

Emily K. Hill, MD, reviews the current US HPV and cervical cancer screening guidelines from the American Cancer Society, American College of Obstetricians and Gynecologists, and the American Society for Colposcopy and Cervical Pathology and discusses the differences within.

Experts in obstetric and gynecologic management examine conventional cervical cancer screening strategies and consider their specificity and sensitivity targets.

Drs Mark H. Stoler, Emily K. Hill, Sangini S. Sheth, and Thomas C. Wright comment on the general awareness around HPV and cervical cancer in patients as well as the importance of increasing routine cervical cancer screening approaching those conversations with patients.

Emily K. Hill, MD; Sangini S. Sheth, MD, MPH, FACOG, and Mark. H. Stoler, MD, FASCP, review the rationale of screening for HPV and vaccinating patients to prevent progression to cervical cancer.

Family history assessment, genetic screening are key to prevention.

Pathology expert Mark H. Stoler, MD, discussed the BD Onclarity™ HPV Assay for primary HPV screening and what it means for the future of cervical cancer detection.

Cancer programs seek to remove barriers to screenings.

A study published in the Journal of Ovarian Research examines factors that may cause endometriosis to progress to ovarian cancer.

Frontline maintenance treatment with selinexor resulted in a statistically significant improvement in median progression-free survival vs placebo in patients with advanced or recurrent endometrial cancer, meeting the primary end point of the phase 3 SIENDO trial.

The campaign emphasizes the importance of annual cancer screenings with the Queen of Hip-Hop Soul

Sarah Lee, MD, MBA, discusses the use of checkpoint inhibitors in endometrial cancer, research regarding the association between MSI-H, dMMR, and TMB-H disease, and the importance of broad molecular testing to ensure all eligible patients are appropriately matched to immunotherapeutic options.

Amer Karam, MD, discusses the role of secondary cytoreductive surgery in ovarian cancer and the need for careful patient selection, plus the results from 3 clinical trials and the key differences between these efforts.

Cortney Eakin, MD, discusses alarming trends in uterine cancer histologies in Black women and some of the potential underlying risk factors at play.

Consensus group discussion resulted in a shift from results-based to risk-based management for cervical cancer screening.

Women are less likely to be diagnosed with bladder cancer, but that does not make the disease any less fatal for this population of patients.